{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:43:33Z","timestamp":1761965013227,"version":"3.37.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/mmy\/myy071","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T07:09:05Z","timestamp":1532416145000},"page":"429-433","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of isavuconazole MIC strips for susceptibility testing of A<i>spergillus<\/i> and S<i>cedosporium<\/i> species"],"prefix":"10.1093","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-8545","authenticated-orcid":false,"given":"L","family":"Trovato","sequence":"first","affiliation":[{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. \u201cPoliclinico-Vittorio Emanuele,\u201d Catania"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Scalia","sequence":"additional","affiliation":[{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. \u201cPoliclinico-Vittorio Emanuele,\u201d Catania"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C I","family":"Palermo","sequence":"additional","affiliation":[{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. \u201cPoliclinico-Vittorio Emanuele,\u201d Catania"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C M","family":"Costanzo","sequence":"additional","affiliation":[{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. \u201cPoliclinico-Vittorio Emanuele,\u201d Catania"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Oliveri","sequence":"additional","affiliation":[{"name":"U.O.C. Laboratory Analysis Unit, A.O.U. \u201cPoliclinico-Vittorio Emanuele,\u201d Catania"},{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"key\n\t\t\t\t2019033016595656200_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019033016595656200_bib2","first-page":"269","article-title":"Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance\u00ae registry analysis","volume":"55","author":"Husain","year":"2017","journal-title":"Medical Mycology"},{"key":"key\n\t\t\t\t2019033016595656200_bib3","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019033016595656200_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13693780802524506","article-title":"Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases","volume":"47","author":"Rodriguez-Tudela","year":"2009","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t2019033016595656200_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkq279","article-title":"Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009","volume":"65","author":"Bueid","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019033016595656200_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/myc.12324","article-title":"Multi-triazole resistant Aspergillus fumigatus infections in Australia","volume":"58","author":"Kidd","year":"2015","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019033016595656200_bib8","doi-asserted-by":"crossref","first-page":"570.e1","DOI":"10.1016\/j.cmi.2016.04.001","article-title":"Azole resistant Aspergillus fumigatus in Denmark: a laboratory based study on resistance mechanisms and genotypes","volume":"22","author":"Jensen","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019033016595656200_bib9","doi-asserted-by":"crossref","first-page":"e10080","DOI":"10.1371\/journal.pone.0010080","article-title":"Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence","volume":"5","author":"Arendrup","year":"2010","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019033016595656200_bib10","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1128\/AAC.02855-14","article-title":"First detection of TR46\/Y121F T289A and TR34\/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment","volume":"58","author":"Astvad","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12281-012-0097-7","article-title":"Azole-resistant invasive aspergillosis: relationship to agriculture","volume":"6","author":"Stensvold","year":"2012","journal-title":"Curr Fungal Infect Rep"},{"key":"key\n\t\t\t\t2019033016595656200_bib12","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AEM.00231-09","article-title":"Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles","volume":"75","author":"Snelders","year":"2009","journal-title":"Appl Environ Microbiol"},{"key":"key\n\t\t\t\t2019033016595656200_bib13","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib14","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib15","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1128\/AAC.03779-14","article-title":"EUCAST testing of isavuconazole susceptibility in Aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density","volume":"58","author":"Arendrup","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11046-010-9324-3","article-title":"Isavuconazole: a comprehensive review of spectrum of activity of a new triazole","volume":"170","author":"Thompson","year":"2010","journal-title":"Mycopathologia"},{"key":"key\n\t\t\t\t2019033016595656200_bib17","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019033016595656200_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"author":"European Medicines Agency","key":"key\n\t\t\t\t2019033016595656200_bib19","article-title":"European public assessment report (EPAR) for Cresemba"},{"key":"key\n\t\t\t\t2019033016595656200_bib20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib22","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019033016595656200_bib23","doi-asserted-by":"crossref","first-page":"e01659","DOI":"10.1128\/AAC.01659-16","article-title":"Evaluation of MIC strip isavuconazole test for susceptibility testing of wild-type and non-wild-type Aspergillus fumigatus isolates","volume":"61","author":"Arendrup","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib24","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1128\/AAC.02855-14","article-title":"First detection of TR46\/Y121F\/T289A and TR34\/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment","volume":"58","author":"Astvad","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib25","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clinical Infectious Diseases"},{"key":"key\n\t\t\t\t2019033016595656200_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/17425255.2012.683859","article-title":"Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections","volume":"8","author":"Livermore","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t2019033016595656200_bib27","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t2019033016595656200_bib29","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019033016595656200_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dki399","article-title":"In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp","volume":"57","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/4\/429\/28252021\/myy071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T17:00:13Z","timestamp":1553965213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/4\/429\/5074492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,8,14]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myy071","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"type":"print","value":"1369-3786"},{"type":"electronic","value":"1460-2709"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2018,8,14]]}}}